Rutong Yu

4.5k total citations
149 papers, 3.2k citations indexed

About

Rutong Yu is a scholar working on Molecular Biology, Cell Biology and Cancer Research. According to data from OpenAlex, Rutong Yu has authored 149 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Molecular Biology, 36 papers in Cell Biology and 33 papers in Cancer Research. Recurrent topics in Rutong Yu's work include Glioma Diagnosis and Treatment (28 papers), Ubiquitin and proteasome pathways (25 papers) and Nanoplatforms for cancer theranostics (24 papers). Rutong Yu is often cited by papers focused on Glioma Diagnosis and Treatment (28 papers), Ubiquitin and proteasome pathways (25 papers) and Nanoplatforms for cancer theranostics (24 papers). Rutong Yu collaborates with scholars based in China, Russia and Netherlands. Rutong Yu's co-authors include Xiuping Zhou, Hongmei Liu, Shangfeng Gao, Xuejiao Liu, Lei Hua, Jun Lü, Qiong Shi, Long Zhang, Jinxia Hu and Hengliang Shi and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rutong Yu

145 papers receiving 3.2k citations

Peers

Rutong Yu

BIOMA

Hugo Guerrero‐Cazares United States

Gino B. Ferraro United States

Mariano S. Viapiano United States

Stanley S. Stylli Australia

Frits Thorsen Norway

Wuqiang Zhu United States

Takeshi Gohongi Japan

Lingna Li United States

Thomas Mathivet France

Hugo Guerrero‐Cazares United States

Rutong Yu

1.8k ×1.0

591 ×0.9

704 ×1.1

332 ×0.6

BIOMA

272 ×0.5

Citations per year, relative to Rutong Yu Rutong Yu (= 1×) peers Hugo Guerrero‐Cazares

Countries citing papers authored by Rutong Yu

Since Specialization

Citations

This map shows the geographic impact of Rutong Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rutong Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rutong Yu more than expected).

Fields of papers citing papers by Rutong Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rutong Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rutong Yu. The network helps show where Rutong Yu may publish in the future.

Co-authorship network of co-authors of Rutong Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Rutong Yu. A scholar is included among the top collaborators of Rutong Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rutong Yu. Rutong Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yin, Jiale, Guohai Liu, Yu Zhou, et al.. (2025). The WW domain presents a promising target for the development of PCIF1 agonists in the treatment of glioma. npj Precision Oncology. 9(1). 329–329.

Yang, Han, et al.. (2025). Application of Multifunctional Metal Nanoparticles in the Treatment of Glioma. International Journal of Nanomedicine. Volume 20. 625–638. 1 indexed citations

Zhang, Long, et al.. (2024). Chronic Stress Exacerbates the Immunosuppressive Microenvironment and Progression of Gliomas by Reducing Secretion of CCL3. Cancer Immunology Research. 12(5). 516–529. 7 indexed citations

Zhang, Junhao, Guoxi Li, Hongyan Jiang, et al.. (2023). Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma. Cell Communication and Signaling. 21(1). 363–363. 15 indexed citations

Zhang, Junhao, Wanzhou Wang, Yang Shen, et al.. (2023). Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment. Journal of Translational Medicine. 21(1). 532–532. 8 indexed citations

Zhang, Long, Yining Zhang, Yi Zhou, et al.. (2023). A Trojan‐Horse‐Like Biomimetic Nano‐NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo‐Immunotherapy. Small. 19(44). e2301439–e2301439. 26 indexed citations

Zhang, Tong, et al.. (2023). Research progress in molecular pathology markers in medulloblastoma. SHILAP Revista de lepidopterología. 4(1). 139–156. 2 indexed citations

Wang, Xiang, Kai Wang, Ji Qi, et al.. (2023). Chronic stress accelerates glioblastoma progression via DRD2/ERK/β-catenin axis and Dopamine/ERK/TH positive feedback loop. Journal of Experimental & Clinical Cancer Research. 42(1). 161–161. 19 indexed citations

Zhou, Ding, Mengmeng Wang, Yu Zhang, et al.. (2021). Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas. Bioscience Reports. 41(5). 12 indexed citations

10.

Zhang, Yu, Yan Wang, Ding Zhou, et al.. (2021). Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 40(27). 4580–4591. 42 indexed citations

11.

Zhang, Caiyi, et al.. (2021). Drug repositioning: Using psychotropic drugs for the treatment of glioma. Cancer Letters. 527. 140–149. 28 indexed citations

12.

Zhou, Junbo, Yue Wu, Liquan Yang, et al.. (2021). A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway. Biochemical Pharmacology. 194. 114795–114795. 5 indexed citations

13.

Liu, Xuejiao, Lin Shi, Guanzheng Liu, et al.. (2020). MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activation. Journal of Cellular and Molecular Medicine. 24(13). 7550–7562. 24 indexed citations

14.

Zhang, Long, Yongkang Zhang, Gang Zhao, et al.. (2020). Preparation of Poly(MTZ)_n–(DMAEMA)_m Micelles and Study on Their Antibacterial Property. ACS Omega. 5(36). 23053–23061. 3 indexed citations

15.

Wang, Jun, Dekang Nie, Xu Song, et al.. (2019). FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling. Biochemical and Biophysical Research Communications. 517(4). 588–595. 11 indexed citations

16.

Zhang, Hao, Jian Gao, Yanhua Qi, et al.. (2016). Expression and significance of Hippo/YAP signaling in glioma progression. Tumor Biology. 37(12). 15665–15676. 57 indexed citations

17.

Wang, Bin, Xiang Zhang, Lei Wang, et al.. (2016). The Ubiquitin Ligase COP1 Promotes Glioma Cell Proliferation by Preferentially Downregulating Tumor Suppressor p53. Molecular Neurobiology. 54(7). 5008–5016. 31 indexed citations

18.

Zhang, Hao, Xu Zhang, Zhiqiang Li, et al.. (2013). NEDD4-1 Regulates Migration and Invasion of Glioma Cells through CNrasGEF Ubiquitination In Vitro. PLoS ONE. 8(12). e82789–e82789. 30 indexed citations

19.

Chen, Maohua, et al.. (2011). Inhibitory effect of hypoxia-induced factor-1α ribozyme on the growth of glioma in nude mice. Scientific Research and Essays. 6(14). 3045–3048. 1 indexed citations

20.

Yu, Rutong, Rui Chen, Qiong Shi, Ting Li, & Hong Tang. (2008). Hammerhead ribozyme targeting human hypoxia inducible factor-1α gene effectively attenuates HeLa xenograft tumors. Surgical Neurology. 72. S8–S16. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact